{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:39:32Z","timestamp":1756809572111},"reference-count":73,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.2217\/17460913.2.3.245","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T07:38:10Z","timestamp":1180078690000},"page":"245-256","source":"Crossref","is-referenced-by-count":7,"title":["Posaconazole for the Management of Mucosal Candidiasis"],"prefix":"10.1080","volume":"2","author":[{"given":"Jose A","family":"Vazquez","sequence":"first","affiliation":[{"name":"Seminar Staff, Henry Ford Hospital, Professor of Medicine, Wayne state University, School of Medicine, Division of Infectious Diseases, 2799\u00a0West Grand Boulevard, CFP-2 Detroit, MI48202\u20132689, USA. Tel.: ; Fax: ;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2007,5,24]]},"reference":[{"key":"e_1_3_1_2_1_1","unstructured":"Odds FC : Candida and Candidosis. A review and bibliography. London. Bailli\u00e8re\u00a0Tindall (1998)."},{"key":"e_1_3_1_2_2_1","doi-asserted-by":"crossref","unstructured":"Vazquez JA SobelJD: Candidiasis. In:\u00a0Clinical Mycology (1st Edition). Dismukes\u00a0WE Pappas PG Sobel JD (Eds). Oxford University Press UK 143\u2013187 (2003).","DOI":"10.1093\/oso\/9780195148091.003.0011"},{"key":"e_1_3_1_2_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-196711000-00023"},{"key":"e_1_3_1_2_4_1","volume-title":"Epidemics (3rd Edition).","author":"Hippocrates CA","year":"1939","unstructured":"Hippocrates CA , AdamsF: In:Epidemics (3rd Edition). Williams and Wilkins, Baltimore, USA (1939)."},{"key":"e_1_3_1_2_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/095646249500600605"},{"key":"e_1_3_1_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(96)80304-0"},{"key":"e_1_3_1_2_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/02681219480000731"},{"key":"e_1_3_1_2_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-7-199604010-00003"},{"key":"e_1_3_1_2_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.23.2.137"},{"key":"e_1_3_1_2_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/380796"},{"key":"e_1_3_1_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90291-K"},{"key":"e_1_3_1_2_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00157408"},{"key":"e_1_3_1_2_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01591361"},{"key":"e_1_3_1_2_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.Supplement_1.S99"},{"key":"e_1_3_1_2_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/516315"},{"key":"e_1_3_1_2_16_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.1.76.30509"},{"key":"e_1_3_1_2_17_1","first-page":"1","article-title":"Epidemiologic overview of resistance to oral antifungal agents in the immunocompromised host.","author":"Vazquez JA","year":"1997","unstructured":"Vazquez JA , SobelJD: Epidemiologic overview of resistance to oral antifungal agents in the immunocompromised host.Excerpta Med.1\u201311 (1997) (Abstract).","journal-title":"Excerpta Med."},{"key":"e_1_3_1_2_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.1.219"},{"key":"e_1_3_1_2_19_1","first-page":"16","volume":"2","author":"Kozinin PJ","year":"1957","unstructured":"Kozinin PJ , TaschdjianCL, DragutskyD et\u00a0al.: Therapy of oral thrush: a comparative evaluation of gentian violet, mycostatin and amphotericin B. Monogr. Ther.2 , 16\u201324 (1957).","journal-title":"Monogr. Ther."},{"key":"e_1_3_1_2_20_1","first-page":"44","volume":"77","author":"Quintiliani R","year":"1994","unstructured":"Quintiliani R , OwensNJ, QuerciaRA et\u00a0al.: Treatment and prevention of oropharyngeal candidiasis. Am.\u00a0J. Med.77(Suppl.\u00a04D) , 44\u201348 (1994).","journal-title":"Am.\u00a0J. Med."},{"key":"e_1_3_1_2_21_1","doi-asserted-by":"publisher","DOI":"10.1086\/513664"},{"key":"e_1_3_1_2_22_1","first-page":"1311","volume":"6","author":"Pons V","year":"1993","unstructured":"Pons V , GreenspanD, DebruinM et\u00a0al.: Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. J.\u00a0Acquir. Immune Defic. Syndr.6 , 1311\u20131316 (1993).","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"e_1_3_1_2_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199401273300407"},{"key":"e_1_3_1_2_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/147.6.1060"},{"key":"e_1_3_1_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92572-5"},{"key":"e_1_3_1_2_26_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/oso\/9780195148091.003.0006","volume-title":"Clinical Mycology (1st Edition).","author":"Como J","year":"2003","unstructured":"Como J , DismukesWE: Azole antifungal drugs. In:Clinical Mycology (1st Edition). Dismukes WE, Pappas PG, Sobel JD (Eds). Oxford University Press, UK 64\u201387 (2003)."},{"key":"e_1_3_1_2_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.4.685"},{"key":"e_1_3_1_2_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500120051025"},{"key":"e_1_3_1_2_29_1","first-page":"452","article-title":"Drug biotransformation by the cytochrome P-450 enzyme system.","author":"Meyer JM","year":"1996","unstructured":"Meyer JM , RodvoldKA: Drug biotransformation by the cytochrome P-450 enzyme system.Infect. Med.452\u2013464 (1996).","journal-title":"Infect. Med."},{"key":"e_1_3_1_2_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.Supplement_3.S334"},{"key":"e_1_3_1_2_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.Supplement_3.S364"},{"key":"e_1_3_1_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(97)80131-2"},{"key":"e_1_3_1_2_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.11.2267"},{"key":"e_1_3_1_2_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1862"},{"key":"e_1_3_1_2_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.2.477"},{"key":"e_1_3_1_2_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1996.tb02973.x"},{"key":"e_1_3_1_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00307-0"},{"key":"e_1_3_1_2_38_1","first-page":"179","volume":"10","author":"Kowalsky SF","year":"1991","unstructured":"Kowalsky SF , DixonDM. Fluconazole: a new antifungal agent. Clin. Pharm.10 , 179\u2013194 (1991).","journal-title":"Clin. Pharm."},{"key":"e_1_3_1_2_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.1.165"},{"key":"e_1_3_1_2_40_1","unstructured":"Voriconazole package insert. Pfizer Inc. NY USA."},{"key":"e_1_3_1_2_41_1","doi-asserted-by":"publisher","DOI":"10.1086\/322653"},{"key":"e_1_3_1_2_42_1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/oso\/9780195148091.003.0007","volume-title":"Clinical Mycology (1st Edition).","author":"Groll AH","year":"2003","unstructured":"Groll AH , WalshTG: Cell wall synthesis inhibitors: echinocandins and nikkomycins. In:Clinical Mycology (1st Edition). Dismukes WE, Pappas PG, Sobel JD (Eds). Oxford University Press, UK 88\u2013103 (2003)."},{"key":"e_1_3_1_2_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1991.tb00940.x"},{"key":"e_1_3_1_2_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2004.00167.x"},{"key":"e_1_3_1_2_45_1","unstructured":"Posaconazole package insert. Schering Corporation NJ USA."},{"key":"e_1_3_1_2_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.3690-3696.2004"},{"key":"e_1_3_1_2_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh027"},{"key":"e_1_3_1_2_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.2.568-574.2004"},{"key":"e_1_3_1_2_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2124-2131.2004"},{"key":"e_1_3_1_2_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.280"},{"key":"e_1_3_1_2_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00163-06"},{"key":"e_1_3_1_2_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3149-3154.2003"},{"key":"e_1_3_1_2_53_1","unstructured":"Courtney R SansoneA RadwanskiE et\u00a0al.: Relative oral bioavailability of three formulations of posaconazole in healthy volunteers: basis for clinical development of the suspension. Presented at: 13th European Congress of Clinical Microbiology and Infectious Diseases. Glasgow Scotland UK 10\u201313 May 2003 (Abstract)."},{"key":"e_1_3_1_2_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.9.2788-2795.2003"},{"key":"e_1_3_1_2_55_1","unstructured":"Courtney R SansoneA CalzettaA et\u00a0al.: The effect of a nutritional supplement (Boost Plus) on the oral bioavailability of posaconazole. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago IL USA 14\u201317 September 2003 (Abstract)."},{"key":"e_1_3_1_2_56_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01977.x"},{"key":"e_1_3_1_2_57_1","author":"Ezzet F","year":"2007","unstructured":"Ezzet F , WexlerD, CourtneyR et\u00a0al.: The oral bioavailability of posaconazole in fasted healthy subjects: basis for clinical dosage recommendations. Clin. Pharmacokinet. (2007) (In Press).","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_1_2_58_1","unstructured":"Krieter P FlanneryB MusickT et\u00a0al.: Pharmacokinetics and excretion of 14C posaconazole following oral administration in healthy male subjects. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego CA USA 27\u201330 September 2002 (Abstract)."},{"key":"e_1_3_1_2_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2004.01.005"},{"key":"e_1_3_1_2_60_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199818020-00001"},{"key":"e_1_3_1_2_61_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200038020-00002"},{"key":"e_1_3_1_2_62_1","unstructured":"Courtney R MartinhoM LimJ et\u00a0al.: Evaluation of the effect of age weights race and gender on posaconazole plasma concentrations in HIV-infected patients. Presented at: 3rd European Congress of Clinical Microbiology and Infectious Diseases. Glasgow Scotland UK 10\u201313 May 2000 (Abstract)."},{"key":"e_1_3_1_2_63_1","unstructured":"Courtney R SansoneA StatkevichP et\u00a0al.: Effect of age and gender on the pharmacokinetics of posaconazole in healthy volunteers. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago IL USA 14\u201317 September 2003 (Abstract)."},{"key":"e_1_3_1_2_64_1","unstructured":"Courtney R SansoneA KantesariaB et\u00a0al.: Effect of ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago IL USA 14\u201317 September 2003 (Abstract)."},{"key":"e_1_3_1_2_65_1","unstructured":"Courtney R LaughlinM GontzH et\u00a0al. Single-dose pharmacokinetics of posaconazole in subjects with various degrees of chronic liver disease. Presented at: Annual Meeting of American Association of Pharmaceutical Scientists. Indianapolis IN USA 29 October\u2013 2 November 2000 (Abstract)."},{"key":"e_1_3_1_2_66_1","unstructured":"Courtney R SansoneA StatkavichP et\u00a0al.: Pharmacokinetics of posaconazole in subjects with varying degrees of renal insufficiency. Presented at: 13th European Congress of Clinical Microbiology and Infectious Diseases. Glasgow Scotland UK 10\u201313 May 2003 (Abstract)."},{"key":"e_1_3_1_2_67_1","doi-asserted-by":"publisher","DOI":"10.1086\/501457"},{"key":"e_1_3_1_2_68_1","doi-asserted-by":"publisher","DOI":"10.1086\/511039"},{"key":"e_1_3_1_2_69_1","author":"Vazquez JA","year":"2007","unstructured":"Vazquez JA , SkiestDJ, Tissot-DupontH et\u00a0al.: Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. HIV Clin. Trials (2007) (In Press).","journal-title":"HIV Clin. Trials"},{"key":"e_1_3_1_2_70_1","doi-asserted-by":"publisher","DOI":"10.1086\/503425"},{"key":"e_1_3_1_2_71_1","doi-asserted-by":"publisher","DOI":"10.1086\/500212"},{"key":"e_1_3_1_2_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061098"},{"key":"e_1_3_1_2_73_1","unstructured":"Pitisuttithum P Gaona-FloresV NegroniR et\u00a0al.: Efficacy of posaconazole in treatment of central nervous system fungal infections: results of an open-label study. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago IL USA 14\u201317 September 2003 (Abstract)."}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/17460913.2.3.245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:38:12Z","timestamp":1719124692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/17460913.2.3.245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,24]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.2217\/17460913.2.3.245"],"URL":"https:\/\/doi.org\/10.2217\/17460913.2.3.245","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,24]]}}}